Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) hit a new 52-week low during trading on Friday. The company traded as low as $9.12 and last traded at $9.13, with a volume of 735,068 shares changing hands. The stock had previously closed at $9.54.
Analyst Ratings Changes
SNDX has been the topic of several research reports. Bank of America reissued a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, November 3rd. HC Wainwright dropped their price objective on shares of Syndax Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating for the company in a research note on Tuesday, November 3rd. UBS Group reaffirmed a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Thursday, October 1st. Finally, JPMorgan Chase & Co. cut their price objective on shares of Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $41.60.
Check Out Our Latest Report on Syndax Pharmaceuticals
Syndax Pharmaceuticals Stock Down 0.9%
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.05). The firm had revenue of $83.30 million for the quarter, compared to analyst estimates of $81.38 million. Syndax Pharmaceuticals had a negative return on equity of 804.38% and a negative net margin of 72.32%. The firm’s quarterly revenue was up 81.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.70) EPS. Sell-side analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.09 EPS for the current year.
Insiders Place Their Bets
In other Syndax Pharmaceuticals news, Director Dennis Podlesak sold 8,000 shares of the firm’s stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $14.21, for a total transaction of $113,680.00. Following the completion of the sale, the director owned 239,763 shares of the company’s stock, valued at $3,407,032.23. This trade represents a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.80% of the company’s stock.
Hedge Funds Weigh In On Syndax Pharmaceuticals
Several large investors have recently modified their holdings of SNDX. BlackRock Inc. acquired a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth about $197,177,000. Bank of America Corp DE purchased a new stake in Syndax Pharmaceuticals in the 2nd quarter valued at about $88,426,000. Elmind Capital LP purchased a new stake in Syndax Pharmaceuticals in the 2nd quarter valued at about $40,550,300. Trails Edge Capital Partners LP acquired a new position in Syndax Pharmaceuticals in the second quarter valued at about $24,264,600. Finally, Algert Global LLC lifted its position in Syndax Pharmaceuticals by 13.2% in the second quarter. Algert Global LLC now owns 1,051,465 shares of the company’s stock valued at $22,985,000 after buying an additional 122,897 shares during the last quarter.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines for cancer and related serious diseases. Its research programs include therapies that target cancer-driving pathways, including menin and the colony-stimulating factor 1 receptor (CSF-1R). The company’s medicines include Revuforj (revumenib), approved in the United States for certain adults and children aged one year and older with relapsed or refractory acute leukemia involving a KMT2A translocation.
Featured Articles
- Five stocks we like better than Syndax Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
